{"filing":{"accession_number":"0001193125-26-281196","cik":"0001885827","ticker":"VRAX","company_name":"Virax Biolabs Group Ltd","form":"6-K","filing_date":"2026-06-24","report_date":null,"primary_document":"6-k_reverse_split_2026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1885827/000119312526281196/6-k_reverse_split_2026.htm"},"events":[{"id":13563,"run_id":12052,"accession_number":"0001193125-26-281196","anchor_item_number":"EX-99.1","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"summary":"The exhibit announces a 1-for-25 share consolidation explicitly undertaken to \"regain compliance with Nasdaq Marketplace Rule 5550(a)(2) (minimum bid price of at least $1 per share) and maintain its listing on the Nasdaq Capital Market.\" This is a direct response to delisting risk triggered by failure to meet the minimum bid price rule, making it a material disclosure of action taken to avoid delisting.","company_name":"Virax Biolabs Group Ltd","ticker":"VRAX","filing_date":"2026-06-24","form":"6-K","submitted_at":null,"items":[{"id":10735,"accession_number":"0001193125-26-281196","item_number":"EX-99.1","item_title":"vrax-ex99_1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The exhibit announces a 1-for-25 share consolidation explicitly undertaken to \"regain compliance with Nasdaq Marketplace Rule 5550(a)(2) (minimum bid price of at least $1 per share) and maintain its listing on the Nasdaq Capital Market.\" This is a direct response to delisting risk triggered by failure to meet the minimum bid price rule, making it a material disclosure of action taken to avoid delisting.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:47:38.668384+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10735,"accession_number":"0001193125-26-281196","item_number":"EX-99.1","item_title":"vrax-ex99_1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The exhibit announces a 1-for-25 share consolidation explicitly undertaken to \"regain compliance with Nasdaq Marketplace Rule 5550(a)(2) (minimum bid price of at least $1 per share) and maintain its listing on the Nasdaq Capital Market.\" This is a direct response to delisting risk triggered by failure to meet the minimum bid price rule, making it a material disclosure of action taken to avoid delisting.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:47:38.668384+00:00","company_name":"Virax Biolabs Group Ltd","ticker":"VRAX","filing_date":"2026-06-24"}]}